Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more
Vericel Corp Ord (VCEL) - Net Assets
Latest net assets as of December 2025: $354.64 Million USD
Based on the latest financial reports, Vericel Corp Ord (VCEL) has net assets worth $354.64 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($487.97 Million) and total liabilities ($133.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $354.64 Million |
| % of Total Assets | 72.68% |
| Annual Growth Rate | 15.42% |
| 5-Year Change | 108.05% |
| 10-Year Change | 1335.27% |
| Growth Volatility | 199.17 |
Vericel Corp Ord - Net Assets Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vericel Corp Ord (1995–2025)
The table below shows the annual net assets of Vericel Corp Ord from 1995 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $354.64 Million | +21.47% |
| 2024-12-31 | $291.97 Million | +29.22% |
| 2023-12-31 | $225.95 Million | +17.52% |
| 2022-12-31 | $192.27 Million | +12.79% |
| 2021-12-31 | $170.46 Million | +26.96% |
| 2020-12-31 | $134.26 Million | +20.86% |
| 2019-12-31 | $111.09 Million | +8.67% |
| 2018-12-31 | $102.23 Million | +353.55% |
| 2017-12-31 | $22.54 Million | -8.78% |
| 2016-12-31 | $24.71 Million | +11.65% |
| 2015-12-31 | $22.13 Million | -37.91% |
| 2014-12-31 | $35.64 Million | +815.28% |
| 2013-12-31 | $3.89 Million | -59.07% |
| 2012-12-31 | $9.51 Million | +173.34% |
| 2011-12-31 | $-12.97 Million | -543.91% |
| 2010-12-31 | $2.92 Million | -83.09% |
| 2009-12-31 | $17.28 Million | -25.93% |
| 2008-12-31 | $23.33 Million | -17.40% |
| 2007-12-31 | $28.25 Million | -33.28% |
| 2006-12-31 | $42.34 Million | +28.20% |
| 2005-12-31 | $33.03 Million | +87.57% |
| 2004-12-31 | $17.61 Million | +52.12% |
| 2003-12-31 | $11.57 Million | +7.15% |
| 2002-12-31 | $10.80 Million | -0.84% |
| 2001-12-31 | $10.89 Million | -12.39% |
| 2000-12-31 | $12.44 Million | +46.11% |
| 1999-12-31 | $8.51 Million | -21.53% |
| 1998-12-31 | $10.85 Million | -42.35% |
| 1997-12-31 | $18.81 Million | +13.34% |
| 1996-12-31 | $16.60 Million | +245.83% |
| 1995-12-31 | $4.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vericel Corp Ord's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34309700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $730.66 Million | 206.03% |
| Other Comprehensive Income | $275.00K | 0.08% |
| Total Equity | $354.64 Million | 100.00% |
Vericel Corp Ord Competitors by Market Cap
The table below lists competitors of Vericel Corp Ord ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viet Nam International Commercial Joint Stock Bank
VN:VIB
|
$1.63 Billion |
|
Inter Parfums Inc
NASDAQ:IPAR
|
$1.63 Billion |
|
Turning Point Brands Inc
NYSE:TPB
|
$1.63 Billion |
|
Mednax Inc
NYSE:MD
|
$1.63 Billion |
|
Energean plc
PINK:EERGF
|
$1.63 Billion |
|
Mycronic AB
LSE:0MQG
|
$1.63 Billion |
|
The Great Eastern Shipping Company Limited
NSE:GESHIP
|
$1.63 Billion |
|
Zhewen Interactive Group Co Ltd
SHG:600986
|
$1.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vericel Corp Ord's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 291,967,000 to 354,640,000, a change of 62,673,000 (21.5%).
- Net income of 16,518,000 contributed positively to equity growth.
- New share issuances of 13,934,000 increased equity.
- Other comprehensive income increased equity by 271,000.
- Other factors increased equity by 31,950,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $16.52 Million | +4.66% |
| Share Issuances | $13.93 Million | +3.93% |
| Other Comprehensive Income | $271.00K | +0.08% |
| Other Changes | $31.95 Million | +9.01% |
| Total Change | $- | 21.47% |
Book Value vs Market Value Analysis
This analysis compares Vericel Corp Ord's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.39x to 4.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $83.01 | $32.50 | x |
| 1996-12-31 | $235.88 | $32.50 | x |
| 1997-12-31 | $267.34 | $32.50 | x |
| 1998-12-31 | $129.86 | $32.50 | x |
| 1999-12-31 | $88.76 | $32.50 | x |
| 2000-12-31 | $85.23 | $32.50 | x |
| 2001-12-31 | $51.22 | $32.50 | x |
| 2002-12-31 | $41.04 | $32.50 | x |
| 2003-12-31 | $36.33 | $32.50 | x |
| 2004-12-31 | $38.22 | $32.50 | x |
| 2005-12-31 | $56.49 | $32.50 | x |
| 2006-12-31 | $63.72 | $32.50 | x |
| 2007-12-31 | $37.82 | $32.50 | x |
| 2008-12-31 | $28.91 | $32.50 | x |
| 2009-12-31 | $19.34 | $32.50 | x |
| 2010-12-31 | $2.36 | $32.50 | x |
| 2011-12-31 | $-6.72 | $32.50 | x |
| 2012-12-31 | $4.62 | $32.50 | x |
| 2013-12-31 | $1.29 | $32.50 | x |
| 2014-12-31 | $3.06 | $32.50 | x |
| 2015-12-31 | $0.93 | $32.50 | x |
| 2016-12-31 | $1.07 | $32.50 | x |
| 2017-12-31 | $0.68 | $32.50 | x |
| 2018-12-31 | $2.54 | $32.50 | x |
| 2019-12-31 | $2.51 | $32.50 | x |
| 2020-12-31 | $2.84 | $32.50 | x |
| 2021-12-31 | $3.67 | $32.50 | x |
| 2022-12-31 | $4.08 | $32.50 | x |
| 2023-12-31 | $4.75 | $32.50 | x |
| 2024-12-31 | $5.65 | $32.50 | x |
| 2025-12-31 | $6.81 | $32.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vericel Corp Ord utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.98%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.38x
- Recent ROE (4.66%) is above the historical average (-94.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -206.25% | -618.75% | 0.26x | 1.27x | $-10.38 Million |
| 1996 | -86.14% | -3575.00% | 0.02x | 1.11x | $-15.96 Million |
| 1997 | -76.01% | -3575.00% | 0.02x | 1.11x | $-16.18 Million |
| 1998 | -158.89% | -6920.88% | 0.02x | 1.14x | $-18.32 Million |
| 1999 | -129.57% | -1251.76% | 0.09x | 1.12x | $-11.88 Million |
| 2000 | -75.51% | -816.52% | 0.09x | 1.08x | $-10.63 Million |
| 2001 | -54.40% | -659.18% | 0.08x | 1.09x | $-7.02 Million |
| 2002 | -73.49% | -905.25% | 0.08x | 1.07x | $-9.02 Million |
| 2003 | -82.76% | -1134.95% | 0.07x | 1.05x | $-10.74 Million |
| 2004 | -59.56% | -805.53% | 0.07x | 1.03x | $-12.25 Million |
| 2005 | -35.76% | -1299.34% | 0.03x | 1.03x | $-15.11 Million |
| 2006 | -38.91% | -1909.04% | 0.02x | 1.06x | $-20.71 Million |
| 2007 | -62.28% | -2568.47% | 0.02x | 1.16x | $-20.42 Million |
| 2008 | -86.28% | -3856.90% | 0.02x | 1.12x | $-22.47 Million |
| 2009 | -92.26% | -8761.54% | 0.01x | 1.12x | $-17.67 Million |
| 2010 | -606.74% | -19920.22% | 0.00x | 11.23x | $-18.02 Million |
| 2011 | 0.00% | -109266.67% | 0.00x | 0.00x | $-18.37 Million |
| 2012 | -309.83% | -140352.38% | 0.00x | 1.60x | $-30.43 Million |
| 2013 | -401.18% | -82221.05% | 0.00x | 2.37x | $-16.01 Million |
| 2014 | -55.89% | -69.18% | 0.61x | 1.33x | $-23.48 Million |
| 2015 | -73.84% | -31.93% | 1.49x | 1.55x | $-18.55 Million |
| 2016 | -79.19% | -35.98% | 1.12x | 1.97x | $-22.04 Million |
| 2017 | -76.69% | -27.04% | 1.17x | 2.42x | $-19.54 Million |
| 2018 | -7.96% | -8.96% | 0.77x | 1.16x | $-18.36 Million |
| 2019 | -8.70% | -8.20% | 0.77x | 1.38x | $-20.77 Million |
| 2020 | 2.13% | 2.31% | 0.60x | 1.53x | $-10.56 Million |
| 2021 | -4.38% | -4.78% | 0.64x | 1.43x | $-24.52 Million |
| 2022 | -8.69% | -10.17% | 0.60x | 1.42x | $-35.94 Million |
| 2023 | -1.41% | -1.61% | 0.56x | 1.57x | $-25.78 Million |
| 2024 | 3.55% | 4.37% | 0.55x | 1.48x | $-18.83 Million |
| 2025 | 4.66% | 5.98% | 0.57x | 1.38x | $-18.95 Million |
Industry Comparison
This section compares Vericel Corp Ord's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vericel Corp Ord (VCEL) | $354.64 Million | -206.25% | 0.38x | $1.63 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |